
Biogen (BIIB) Stock Forecast & Price Target
Biogen (BIIB) Analyst Ratings
Bulls say
Biogen is expected to have a strong future due to its diverse portfolio, including successful treatments for multiple sclerosis and promising candidates in late-stage development for Alzheimer's and lupus. Despite potential risks in the immunology field, the company has shown a dedication to innovation and community impact which has contributed to positive market response and outlook. With consistent revenue growth from its established franchises and potential new additions, Biogen has the potential for strong financial performance in the coming years.
Bears say
Biogen is facing several challenges that could impact its stock performance in the near and long term. These include a declining multiple sclerosis franchise, reliance on one revenue-generating collaboration agreement with Roche, and heavy competition in the rare disease space. The potential success of its newer franchises is uncertain, and their market potential may not be significant enough to offset the declines in the company's core MS business. Additionally, there are risks related to clinical failures or reimbursement limitations for key pipeline products, as well as potential negative impacts from competition, generics, and pricing pressures. Despite recent strategic initiatives and potential upside from its Alzheimer's franchise, these challenges may continue to weigh on Biogen's stock performance.
This aggregate rating is based on analysts' research of Biogen and is not a guaranteed prediction by Public.com or investment advice.
Biogen (BIIB) Analyst Forecast & Price Prediction
Start investing in Biogen (BIIB)
Order type
Buy in
Order amount
Est. shares
0 shares